144 related articles for article (PubMed ID: 23147755)
1. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
[No Abstract] [Full Text] [Related]
2. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
3. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.
Cassano N; Vena GA
Int J Dermatol; 2008 Sep; 47(9):980-1. PubMed ID: 18937672
[No Abstract] [Full Text] [Related]
4. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis: a brief history, II.
Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
Cutis; 2001 Dec; 68(6):367-72. PubMed ID: 11775769
[TBL] [Abstract][Full Text] [Related]
6. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
[TBL] [Abstract][Full Text] [Related]
7. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
Yamauchi PS; Gindi V; Lowe NJ
Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
[TBL] [Abstract][Full Text] [Related]
8. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
9. Etanercept use for psoriasis in Taiwan: a case series study.
Chiu HY; Wang TS; Cho YT; Tsai TF
Int J Dermatol; 2013 Jun; 52(6):673-80. PubMed ID: 22348620
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
Strober BE
Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up.
Puig L; Camacho Martínez FM; Gimeno Carpio E; López-Ávila A; García-Calvo C
Dermatology; 2012; 225(3):220-30. PubMed ID: 23235195
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severe nail psoriasis with etanercept.
Coelho JD; Diamantino F; Lestre S; Ferreira AM
Indian J Dermatol Venereol Leprol; 2011; 77(1):72-4. PubMed ID: 21220889
[No Abstract] [Full Text] [Related]
13. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
[TBL] [Abstract][Full Text] [Related]
14. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
15. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
Krueger GG; Elewski B; Papp K; Wang A; Zitnik R; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
[TBL] [Abstract][Full Text] [Related]
16. Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin.
Antoniou C; Nicolaidou E; Moustou AE; Stratigos A; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):854-5. PubMed ID: 19646137
[No Abstract] [Full Text] [Related]
17. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
[No Abstract] [Full Text] [Related]
18. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
Gilbert KE; Manalo IF; Wu JJ
J Am Acad Dermatol; 2015 Aug; 73(2):329-31. PubMed ID: 26183982
[No Abstract] [Full Text] [Related]
20. Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.
Abbasi NR; Orlow SJ
Pediatr Dermatol; 2009; 26(1):118. PubMed ID: 19250435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
